name: BRAF V600E-Mutant Colorectal Cancer
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-02-27T21:52:53Z'
description: >-
  BRAF V600E-mutant colorectal cancer is a molecularly defined subtype representing approximately
  8-12% of all colorectal cancers. The V600E mutation causes constitutive activation of BRAF
  kinase, driving the MAPK signaling pathway independent of upstream RAS signaling. This subtype
  has historically been associated with poor prognosis, chemotherapy resistance, and limited
  treatment options. The combination of encorafenib (BRAF inhibitor) and cetuximab (anti-EGFR)
  has transformed outcomes for these patients by addressing the feedback reactivation that
  limits single-agent BRAF inhibitor efficacy seen in melanoma.
categories:
- Gastrointestinal Cancer
- Colorectal Cancer
- Molecularly Defined Cancer
parents:
- colorectal adenocarcinoma
has_subtypes:
- name: MSI-H BRAF V600E CRC
  description: >-
    BRAF V600E mutation with concurrent microsatellite instability-high status, typically from
    MLH1 promoter hypermethylation. Better prognosis than MSS BRAF-mutant CRC, responds to
    immune checkpoint inhibitors.
- name: MSS BRAF V600E CRC
  description: >-
    BRAF V600E mutation with microsatellite stable (MSS) status. Represents the majority of
    BRAF-mutant CRC with aggressive behavior, poor response to chemotherapy, and need for
    targeted therapy approaches.
pathophysiology:
- name: BRAF V600E Constitutive Activation
  description: >-
    The V600E mutation substitutes glutamic acid for valine at position 600 in the activation
    segment of BRAF kinase. This mimics phosphorylation-induced activation, locking BRAF in
    an active conformation. The mutant kinase signals constitutively through MEK and ERK
    without upstream RAS activation.
  evidence:
  - reference: PMID:30739887
    supports: PARTIAL
    snippet: BRAF mutations confers a poor prognosis in Western CRC patients, particularly in metastatic CRC (mCRC) and its mutations occur in approximately 4-20% CRC, with the vast majority being the V600E hotspot mutation.
    explanation: This abstract links BRAF mutations in CRC to the V600E hotspot and supports the relevance of V600E in colorectal cancer.
  cell_types:
  - preferred_term: colon epithelial cell
    term:
      id: CL:0011108
      label: colon epithelial cell
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  downstream:
  - target: Uncontrolled MAPK Pathway Signaling
    description: Constitutive BRAF activation drives sustained MEK/ERK signaling
- name: Uncontrolled MAPK Pathway Signaling
  description: >-
    Constitutive BRAF V600E activation leads to continuous phosphorylation of MEK1/2, which
    phosphorylates ERK1/2. Activated ERK translocates to the nucleus and drives expression
    of genes promoting cell proliferation, survival, and invasion. This signaling is
    independent of growth factor receptor activation.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  - preferred_term: signal transduction
    modifier: INCREASED
    term:
      id: GO:0007165
      label: signal transduction
  downstream:
  - target: Enhanced Cell Proliferation
    description: ERK activation drives cell cycle progression and proliferation
  - target: EGFR Feedback Reactivation
    description: ERK inhibition releases negative feedback on EGFR
- name: Enhanced Cell Proliferation
  description: >-
    Sustained ERK signaling promotes entry into the cell cycle by inducing cyclin D1 and
    other proliferative genes while suppressing cell cycle inhibitors. This drives continuous
    tumor cell division independent of external growth signals.
  locations:
  - preferred_term: colon
    term:
      id: UBERON:0001155
      label: colon
- name: EGFR Feedback Reactivation
  description: >-
    Unlike melanoma, colorectal cancer cells have high EGFR expression. When BRAF is inhibited,
    relief of ERK-mediated negative feedback leads to rapid EGFR reactivation, which signals
    through RAS and CRAF to restore MAPK pathway activity. This explains why BRAF inhibitor
    monotherapy fails in colorectal cancer but works in melanoma.
  biological_processes:
  - preferred_term: ERBB signaling pathway
    modifier: INCREASED
    term:
      id: GO:0038127
      label: ERBB signaling pathway
  notes: >-
    This feedback mechanism necessitates combination therapy with EGFR inhibitors (cetuximab)
    to block the reactivation pathway.
histopathology:
- name: Adenocarcinoma
  finding_term:
    preferred_term: Adenocarcinoma
    term:
      id: NCIT:C2852
      label: Adenocarcinoma
  frequency: VERY_FREQUENT
  description: Adenocarcinoma is the most common pathologic subtype of colon cancer.
  evidence:
  - reference: PMID:35613396
    supports: SUPPORT
    snippet: "Adenocarcinoma is the most common pathologic subtype of colon cancer"
    explanation: Abstract reports adenocarcinoma as the most common pathologic subtype of colon cancer.

phenotypes:
- category: Gastrointestinal
  name: Colon Cancer
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    BRAF V600E colorectal cancer shows strong predilection for the right colon (proximal colon).
    Tumors are often diagnosed at advanced stage with peritoneal and distant lymph node
    metastases.
  phenotype_term:
    preferred_term: Colon cancer
    term:
      id: HP:0003003
      label: Colon cancer
- category: Gastrointestinal
  name: Abdominal Pain
  frequency: FREQUENT
  description: >-
    Abdominal discomfort from tumor mass effect, particularly with bulky right-sided tumors.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
- category: Hematologic
  name: Anemia
  frequency: FREQUENT
  description: >-
    Iron deficiency anemia from chronic occult blood loss is common, particularly as right-sided
    tumors may bleed without visible hematochezia.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
- category: Constitutional
  name: Weight Loss
  frequency: FREQUENT
  description: >-
    Unintentional weight loss is common, reflecting the aggressive nature of BRAF-mutant disease
    and frequent presentation at advanced stage.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Constitutional
  name: Fatigue
  frequency: FREQUENT
  description: >-
    Fatigue from anemia, advanced disease burden, or tumor-related cachexia.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
biochemical:
- name: BRAF V600E Mutation Detection
  notes: >-
    BRAF V600E mutation is detected by PCR, immunohistochemistry (VE1 antibody), or
    next-generation sequencing. Testing should be performed on all metastatic CRC to guide
    treatment selection.
- name: MSI/MMR Testing
  notes: >-
    All BRAF V600E tumors should be tested for MSI/MMR status as MSI-H BRAF-mutant tumors
    have better prognosis and respond to immunotherapy. MSS BRAF-mutant tumors require
    targeted therapy approaches.
genetic:
- name: BRAF V600E
  association: Somatic Activating Mutation
  notes: >-
    The BRAF V600E mutation (c.1799T>A, p.V600E) accounts for more than 90% of BRAF mutations
    in colorectal cancer. It is mutually exclusive with RAS mutations. The mutation results
    in approximately 500-fold increased kinase activity compared to wild-type BRAF.
  evidence:
  - reference: PMID:32674932
    supports: PARTIAL
    snippet: "The BRAFV600E mutation, observed in 8Â % of colorectal cancers (CRC), introduces a particular phenotype and a poor prognosis at the localized or metastatic stage."
    explanation: "Abstract reports BRAF V600E frequency and associated poor prognosis in colorectal cancer."
- name: PIK3CA
  association: Co-occurring Somatic Mutations
  notes: >-
    PIK3CA mutations co-occur with BRAF V600E in approximately 20% of cases, potentially
    conferring resistance to MAPK pathway inhibition through parallel PI3K pathway activation.
- name: PTEN
  association: Co-occurring Loss of Function
  notes: >-
    PTEN loss may co-occur with BRAF V600E, activating the PI3K pathway and potentially
    contributing to treatment resistance.
treatments:
- name: Encorafenib plus Cetuximab
  description: >-
    FDA-approved combination for BRAF V600E metastatic CRC after prior therapy. Encorafenib
    inhibits mutant BRAF while cetuximab blocks EGFR to prevent feedback reactivation. BEACON
    CRC trial demonstrated significant improvement in overall survival and response rate
    compared to standard chemotherapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: encorafenib
      term:
        id: NCIT:C98283
        label: Encorafenib
    - preferred_term: cetuximab
      term:
        id: NCIT:C1723
        label: Cetuximab
- name: Encorafenib plus Cetuximab plus Binimetinib
  description: >-
    Triple combination adding the MEK inhibitor binimetinib to encorafenib and cetuximab.
    Provides more complete MAPK pathway suppression. Originally studied in BEACON CRC but
    doublet (encorafenib/cetuximab) is preferred due to similar efficacy with less toxicity.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: encorafenib
      term:
        id: NCIT:C98283
        label: Encorafenib
    - preferred_term: cetuximab
      term:
        id: NCIT:C1723
        label: Cetuximab
    - preferred_term: binimetinib
      term:
        id: CHEBI:145371
        label: binimetinib
- name: FOLFOXIRI plus Bevacizumab
  description: >-
    Intensive triplet chemotherapy (5-FU, leucovorin, oxaliplatin, irinotecan) with bevacizumab
    may provide benefit for fit patients with BRAF V600E mCRC who can tolerate aggressive
    therapy. TRIBE2 showed benefit in this subgroup.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
- name: Surgical Resection
  description: >-
    Surgery for localized disease or oligometastatic disease in selected patients. Adjuvant
    chemotherapy is standard for stage III disease, though BRAF-mutant tumors may have
    attenuated benefit.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
disease_term:
  preferred_term: BRAF V600E-mutant colorectal cancer
  term:
    id: MONDO:0005575
    label: colorectal cancer

classifications:
  icdo_morphology:
    classification_value: Adenocarcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
